{"id":"perindopril-tablet","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Dry cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Fatigue"},{"rate":"0.1-0.5","effect":"Angioedema"}]},"_chembl":{"chemblId":"CHEMBL1581","moleculeType":"Small molecule","molecularWeight":"368.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ACE inhibitors block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, resulting in lower blood pressure and reduced cardiac workload. The drug also has cardioprotective and renal-protective effects.","oneSentence":"Perindopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:06.683Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Post-myocardial infarction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":"Apparent Resistant Hypertension, Hypertension, High Blood Pressure","enrollment":142},{"nctId":"NCT05288400","phase":"PHASE3","title":"Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.","status":"COMPLETED","sponsor":"Servier","startDate":"2018-05-14","conditions":"Essential Hypertension","enrollment":150},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT06213610","phase":"PHASE1","title":"Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2024-01-09","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT04591808","phase":"PHASE3","title":"Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia","status":"TERMINATED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2021-09-09","conditions":"Dyslipidemias, Hypertension","enrollment":146},{"nctId":"NCT05940909","phase":"PHASE1","title":"Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2023-06-24","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT05470764","phase":"PHASE1","title":"Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-05-30","conditions":"Bioequivalence, Healthy Subjects","enrollment":52},{"nctId":"NCT05464745","phase":"PHASE1","title":"Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-05-19","conditions":"Bioequivalence, Healthy Subjects","enrollment":42},{"nctId":"NCT05053893","phase":"NA","title":"Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-09-22","conditions":"Cardio-Renal Syndrome","enrollment":40},{"nctId":"NCT04556110","phase":"PHASE1","title":"A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on After Meals in Healthy Subjects","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2018-11-20","conditions":"Healthy","enrollment":32},{"nctId":"NCT04556058","phase":"PHASE1","title":"A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on an Empty Stomach in Healthy Subjects","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2018-11-29","conditions":"Healthy","enrollment":32},{"nctId":"NCT03738761","phase":"PHASE4","title":"Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine","status":"COMPLETED","sponsor":"KRKA","startDate":"2018-02-13","conditions":"Hypertension","enrollment":471},{"nctId":"NCT00461903","phase":"PHASE3","title":"Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Montreal Heart Institute","startDate":"2007-12","conditions":"Essential Hypertension, Atrial Fibrillation","enrollment":316},{"nctId":"NCT04254042","phase":"PHASE4","title":"Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients.","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2018-10-01","conditions":"Hypertension","enrollment":24},{"nctId":"NCT04222686","phase":"PHASE4","title":"Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2017-12-20","conditions":"Type 2 Diabetes Mellitus","enrollment":23},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT03747978","phase":"PHASE4","title":"Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2016-10-01","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":30},{"nctId":"NCT01013155","phase":"NA","title":"Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-05","conditions":"Essential Hypertension","enrollment":48},{"nctId":"NCT01012687","phase":"NA","title":"Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-04","conditions":"Essential Hypertension","enrollment":48},{"nctId":"NCT03393715","phase":"PHASE4","title":"Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":20},{"nctId":"NCT02777489","phase":"PHASE2","title":"Influence of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects","status":"TERMINATED","sponsor":"Gene PreDiT","startDate":"2016-02-18","conditions":"Obesity","enrollment":140},{"nctId":"NCT02995954","phase":"PHASE4","title":"Fixed vs Free Dose of ACEi/CCB Combination Therapy","status":"COMPLETED","sponsor":"Guido Iaccarino","startDate":"2014-01","conditions":"Hypertension","enrollment":100},{"nctId":"NCT01583114","phase":"PHASE3","title":"PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors","status":"TERMINATED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-12","conditions":"Dilated Cardiomyopathy","enrollment":6},{"nctId":"NCT02502110","phase":"PHASE4","title":"Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2015-08","conditions":"Paroxysmal Atrial Fibrillation","enrollment":346},{"nctId":"NCT02299310","phase":"PHASE4","title":"Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2014-11","conditions":"Chronic Kidney Disease","enrollment":60},{"nctId":"NCT01682577","phase":"NA","title":"Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2008-09","conditions":"Healthy","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"MALAISE"},{"count":7,"reaction":"DYSPNOEA"},{"count":6,"reaction":"DIARRHOEA"},{"count":6,"reaction":"RHABDOMYOLYSIS"},{"count":5,"reaction":"ABDOMINAL PAIN"},{"count":5,"reaction":"ACUTE KIDNEY INJURY"},{"count":5,"reaction":"ANGIOEDEMA"},{"count":5,"reaction":"DRUG INTERACTION"},{"count":5,"reaction":"HYPONATRAEMIA"},{"count":5,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["The test product","Coversyl 10 mg"],"phase":"marketed","status":"active","brandName":"Perindopril tablet","genericName":"Perindopril tablet","companyName":"Pharmtechnology LLC","companyId":"pharmtechnology-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perindopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure. Used for Hypertension, Chronic heart failure, Stable coronary artery disease (secondary prevention).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}